X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (373) 373
Publication (96) 96
Book Review (31) 31
Patent (26) 26
Conference Proceeding (13) 13
Book Chapter (3) 3
Book / eBook (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (226) 226
humans (194) 194
oncology (126) 126
animals (98) 98
article (88) 88
mutation (85) 85
female (79) 79
lung neoplasms - drug therapy (75) 75
mice (71) 71
cell line, tumor (65) 65
lung neoplasms - genetics (60) 60
male (60) 60
carcinoma, non-small-cell lung - drug therapy (55) 55
cell biology (51) 51
cancer (50) 50
lung cancer (45) 45
carcinoma, non-small-cell lung - genetics (44) 44
middle aged (44) 44
gefitinib (43) 43
protein kinase inhibitors - pharmacology (40) 40
protein kinase inhibitors - therapeutic use (40) 40
aged (38) 38
acquired-resistance (37) 37
cell lung-cancer (37) 37
research (35) 35
tumors (35) 35
adult (34) 34
antineoplastic agents - therapeutic use (34) 34
biochemistry & molecular biology (33) 33
drug resistance, neoplasm - genetics (33) 33
receptor, epidermal growth factor - genetics (33) 33
receptor, epidermal growth factor - antagonists & inhibitors (32) 32
mutations (31) 31
egfr (30) 30
lung neoplasms - pathology (30) 30
antineoplastic agents - pharmacology (27) 27
phosphatidylinositol 3-kinases - metabolism (27) 27
lung neoplasms - metabolism (26) 26
apoptosis (24) 24
care and treatment (24) 24
neoplasms (24) 24
respiratory tract diseases (24) 24
activation (23) 23
mice, nude (23) 23
signal transduction (23) 23
aged, 80 and over (22) 22
drug resistance (22) 22
multidisciplinary sciences (22) 22
carcinoma, non-small-cell lung - pathology (21) 21
cells (21) 21
chemistry (21) 21
chemotherapy (21) 21
drug resistance, neoplasm (21) 21
genetic aspects (21) 21
human necessities (21) 21
hygiene (21) 21
medical or veterinary science (21) 21
microbiology (21) 21
phosphatidylinositol 3-kinases - antagonists & inhibitors (21) 21
phosphatidylinositol 3-kinases - genetics (21) 21
preparations for medical, dental, or toilet purposes (21) 21
resistance (21) 21
treatment outcome (21) 21
xenograft model antitumor assays (20) 20
receptor protein-tyrosine kinases - genetics (19) 19
signal transduction - drug effects (19) 19
abridged index medicus (18) 18
apoptosis - drug effects (18) 18
carcinoma, non-small-cell lung - metabolism (18) 18
erlotinib (18) 18
gene (18) 18
medicine, research & experimental (18) 18
phosphorylation (18) 18
proteins (18) 18
receptor, epidermal growth factor - metabolism (18) 18
sensitivity (18) 18
specific therapeutic activity of chemical compounds ormedicinal preparations (18) 18
beer (17) 17
biochemistry (17) 17
compositions or test papers therefor (17) 17
condition-responsive control in microbiological orenzymological processes (17) 17
crizotinib (17) 17
enzymology (17) 17
measuring or testing processes involving enzymes, nucleicacids or microorganisms (17) 17
metallurgy (17) 17
mutation or genetic engineering (17) 17
neoplasms - drug therapy (17) 17
processes of preparing such compositions (17) 17
proto-oncogene proteins - genetics (17) 17
pyridines - therapeutic use (17) 17
spirits (17) 17
vinegar (17) 17
wine (17) 17
caveolins (16) 16
drug therapy (16) 16
growth (16) 16
growth-factor receptor (16) 16
health aspects (16) 16
in-vivo (16) 16
kinases (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New England Journal of Medicine, ISSN 0028-4793, 2014, Volume 370, Issue 26, pp. 2537 - 2539
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | EGFR MUTATIONS | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | IMMUNOHISTOCHEMISTRY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 07/2008, Volume 118, Issue 7, pp. 2609 - 2619
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 11/2011, Volume 121, Issue 11, pp. 4311 - 4321
Therapies inhibiting receptor tyrosine kinases (RTKs) are effective against some human cancers when they lead to simultaneous downregulation of PI3K/AKT and... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | BREAST-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | GROWTH-FACTOR RECEPTOR | ONCOGENIC ACTIVATION | MUTATION STATUS | CYCLIN D1 | RAS | PHOSPHATIDYLINOSITOL 3-KINASE | ACQUIRED-RESISTANCE | Neoplasm Transplantation | RNA, Small Interfering - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Male | Transplantation, Heterologous | DNA Primers - genetics | Phosphatidylinositol 3-Kinases - metabolism | Gene Knockdown Techniques | MAP Kinase Signaling System | Base Sequence | Colorectal Neoplasms - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Colorectal Neoplasms - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | ras Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Phosphatidylinositol 3-Kinases - genetics | Animals | Class I Phosphatidylinositol 3-Kinases | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Colorectal Neoplasms - pathology | Apoptosis | Tyrosine | Care and treatment | Gene mutations | Colorectal cancer | Cellular signal transduction | Genetic aspects | Research | Diagnosis | Properties | Genetic regulation | Identification and classification | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7391, pp. 570 - 575
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2011, Volume 108, Issue 18, pp. 7535 - 7540
The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of... 
Tumor cell line | Medical treatment | Cell lines | Small interfering RNA | Genetic mutation | Viability | Oncogenes | Lung neoplasms | Tumors | Cancer | ANAPLASTIC LYMPHOMA KINASE | ALK | GEFITINIB | MET AMPLIFICATION | SOLID TUMORS | MULTIDISCIPLINARY SCIENCES | MUTATION | ACQUIRED-RESISTANCE | INHIBITORS | EGFR | CHRONIC MYELOID-LEUKEMIA | RNA, Small Interfering - genetics | Pyrazoles - therapeutic use | Apoptosis - drug effects | Humans | Immunoblotting | Antineoplastic Agents - therapeutic use | DNA Primers - genetics | Dose-Response Relationship, Drug | Flow Cytometry | Transfection | Organophosphorus Compounds - pharmacology | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Pyrazoles - pharmacology | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | In Situ Hybridization, Fluorescence | Pyrimidines - pharmacology | Mutation - genetics | Reverse Transcriptase Polymerase Chain Reaction | Drug Resistance, Neoplasm - genetics | Animals | Signal Transduction - drug effects | Mice, Nude | Oncogene Proteins, Fusion - genetics | Survival Analysis | Cell Line, Tumor | Oncogene Proteins, Fusion - antagonists & inhibitors | Mice | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Patient outcomes | Genetic aspects | Dosage and administration | Management | Research | Lung cancer, Non-small cell | Drug therapy | Antineoplastic agents | Drug resistance | Proteins | Lung cancer | Mutation | Kinases | Gene expression | Cells | Index Medicus | Biological Sciences
Journal Article
Nature Medicine, ISSN 1078-8956, 01/2012, Volume 18, Issue 1, pp. 74 - 82
Journal Article